<DOC>
	<DOCNO>NCT00254982</DOCNO>
	<brief_summary>This open-label , multicenter , parallel-group comparison study efficacy , safety , tolerability infliximab therapy adult patient suffer chronic plaque psoriasis ( psoriasis vulgaris ) . Patients assign GROUP I ( `` high need '' ) GROUP II ( `` low-need '' ) investigator accord previous psoriasis treatment .</brief_summary>
	<brief_title>Infliximab High Need Versus Low Need Psoriasis Patients : The IHELP Study ( Study P04320 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Written inform consent patient study participation , prior protocol specific procedure . Patients 18 year age old time enrollment , may male female race . Diagnosis plaquetype psoriasis ( psoriasis vulgaris ) least 6 month prior screen . Plaquetype psoriasis cover least 10 % total body surface area . Psoriasis Area Severity Index ( PASI ) Score 12 great . GROUP I ( `` high need '' ) patient : adult patient moderate severe plaque psoriasis either control , intolerant contraindication least two currently available systemic therapy ( e.g . photochemotherapy , cyclosporine , methotrexate , oral retinoids , fumaric acid ester , efalizumab , etanercept ) . GROUP II ( `` low need '' ) patient : adult patient moderate severe plaque psoriasis undergone pretreatment one currently available systemic therapy ( e.g . photochemotherapy , cyclosporine , methotrexate , oral retinoids , fumaric acid ester , efalizumab , etanercept ) . A patient showing contraindication towards two systemic treatment , never pretreated systemic therapy assign GROUP II ( `` low need '' ) . Patients must chest xray ( preferably posteroanterior lateral ) within 3 month prior first infusion evidence malignancy , infection ( e.g . tuberculosis ) fibrosis . Laboratory test result : liver enzyme ( aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , gamma glutamyl transferase ( GGT ) alkaline phosphatase ) must within 1.5 time upper limit normal range ( ULN ) , total bilirubin &lt; =1.0 ULN , serum creatinine &lt; 1.5 mg/dL ( must available Baseline ) . Patients must agree avoid prolonged sun exposure ultraviolet light source study . Women childbearing potential must agree use medically accept method contraception prior screening , receive protocolspecified medication , six month stop medication . Acceptable method contraception include abstinence , condom ( male female ) without spermicidal agent , diaphragm cervical cap spermicide , medically prescribe intrauterine device ( IUD ) , oral injectable hormonal contraceptive , surgical sterilization ( e.g . hysterectomy tubal ligation ) . Women childbearing potential must negative serum pregnancy test ( betahuman chorionic gonadotropin [ hCG ] ) Screening ( must available Baseline ) . Baseline PASIScore 12 great . Patients suffer active latent tuberculosis . Prior start treatment infliximab tuberculosis need exclude follow recommendation publish German Paul Ehrlich Institute . Patients serious infection ( e.g . abscess , pneumonia pyelonephritis ) hospitalize receive treatment intravenous antibiotic previous 2 month . Patients know infected human immunodeficiency virus , hepatitis B C virus , prior current opportunistic infection ( within last six month , Herpes zoster within last 2 month ) . Patients suffer congestive heart failure include medically control asymptomatic patient . History demyelinate disease symptom suggestive multiple sclerosis optic neuritis . Patients current sign symptom history systemic lupus erythematosus . Patients suffer nonplaque psoriasis , e.g . erythrodermic , guttate pustular form . The presence psoriasisarthritis exclusion criterion . Patients suffer current drug induce psoriasis ( e.g . new onset psoriasis exacerbation psoriasis betablockers calciumchannelblockers ) . If patient take one substance regular basis , stable dose least three week prior Baseline . Patients suffer severe , progressive uncontrolled renal , hepatic , hematological , gastrointestinal , endocrine , pulmonary , cardiac , neurological , cerebral psychiatric disease , , opinion investigator , would interfere study evaluation safe optimal participation study . Any known malignancy last five year ( except basal cell carcinoma ) , history lymphoproliferative disease . Patients receive systemic psoriasis therapy ( e.g . immunosuppressant ) lithium within 28 day baseline visit . Patients pretreated etanercept efalizumab within 28 day Baseline . Patients previously treat infliximab . Patients use topical treatment could affect PASI evaluation ( e.g . corticosteroid , anthralin , topical vitamin D derivates ) within 2 week baseline visit , except special area like head hand . Patients used investigational drug within 3 month Baseline . Patients allergy/sensitivity study drug excipients . Women breastfeed , pregnant , intend become pregnant . Patients clinically significant condition situation , condition study . Patients participate clinical study . Patients part staff personnel directly involve study . Patients family member investigational study staff . Patients used investigational drug within 3 month Baseline . Patients receive systemic psoriasis therapy ( e.g . immunosuppressant ) lithium within 28 day baseline visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>